首页|"安神通络方"治疗风痰阻络型脑卒中后焦虑障碍的临床观察

"安神通络方"治疗风痰阻络型脑卒中后焦虑障碍的临床观察

扫码查看
目的:观察安神通络方(ASTLF)治疗风痰阻络型脑卒中后焦虑障碍的临床疗效.方法:将160例符合纳入标准的风痰阻络型脑卒中后焦虑障碍(PSAD)的患者随机分为治疗、对照2个组,每组80例,分别给予安神通络方(口服中药饮片:安神通络方)和口服盐酸氟西汀治疗,疗程均为4周,分期测试并记录汉密尔顿焦虑量表(HAMA)和副反应量表(TESS)得分,以最终结果判定疗效以及不良反应.结果:经过4周后治疗后,同组治疗前后HAMA分值均较治疗前降低,差异显著(P均<0.01);两组之间治疗后比较显示,差异无统计学意义.治疗组与对照组TESS量表评分比较差异有统计学意义(P<0.05).结论:安神通络方治疗风痰阻络型脑卒中后焦虑障碍(PSAD)安全、有效,而且不良反应更少,值得进一步研究和临床推广.
Objective:To observe the clinical efficacy of medicationat the Anshentongluo therapy in treating Fengtanzuluo-post-stroke anxiety disorder(PSAD).Method:160 patients were randomized into 2 groups on average,the Anshentongluo therapy group was intervened by oral use of Anshentongluofang;and The Western medication group was intervened by oral use of fluoxertine hydrochloride.The therapeutic efficacy and side effects were evaluated with Hamilton Anxiety Scale(HAMA)and treatment emergent symptom scale(TESS).Results:After the intervention of 4 weeks,the HAMA decrease values in two groups were less than those before the treatment(P<0.01).There was on significant difference in response rate between the 2 groups.There was significant difference in TESS between the 2 groups.Conclusion:Anshentongluo therapy is one of the effective therapies with less emergent symptom in treating Fengtanzuluo-PSAD,which is worth studying and spreading further more.

StrokeAnxietytraditional Chinese medicine

张雪、王雅仙、林坚

展开 >

福州市第一总医院 福州 350001

脑卒中 焦虑障碍 中药治疗

2023

黑龙江中医药
黑龙江省中医研究院

黑龙江中医药

影响因子:0.425
ISSN:1000-9906
年,卷(期):2023.52(5)
  • 18